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To investigate the mechanisms underlying itching in 
atopic dermatitis, we examined whether thromboxane 
(TX) A2, an arachidonic acid metabolite, is involved in 
spontaneous scratching, an itch-related response, in NC 
mice with atopic dermatitis-like skin lesions. The TXA2 
receptor (TP) antagonist ONO-3708 inhibited the spon-
taneous scratching. The mRNA expression of TX syntha-
se (TXSyn) distributed mainly in epidermis and the con-
centration of TXB2, a metabolite of TXA2, were increased 
in lesional skin. Scratching caused by the PAR2 agonist 
SLIGRL-NH2 was suppressed by ONO-3708. SLIGRL-
NH2-induced scratching decreased approximately 75% 
in TP-deficient mice, compared to wild-type mice. In 
primary cultures of mouse keratinocytes, SLIGRL-NH2 
induced the production of TXA2, as evidenced by the in-
creased TXB2, which was inhibited by the TXSyn inhi-
bitor sodium ozagrel and a PAR2-neutralizing antibody. 
Taken together, these results suggest that epidermal 
TXA2, which may be produced via PAR2 activation, is 
involved in itching in atopic dermatitis. Key words: itch; 
thromboxane A2; TP receptor; thromboxane synthase; 
atopic dermatitis; proteinase-activated receptor 2.
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Atopic dermatitis (AD) is a severe, chronic inflammatory 
skin disease and itching constitutes its major diagnostic 
criterion (1–3). In AD patients, scratching induced by 
the itch sensation aggravates dermatitis and increases the 
frequency of itching (4). Therefore, itch control is very 
important for improving quality of life and treating AD. 
Although H1 histamine receptor antagonists often serve 
as the drug of first choice for treating itching, AD-derived 
itching responds poorly to these drugs (5), suggesting 
that histamine is not essential for AD itching. Therefore, 
a comprehensive understanding of the mechanisms and 
mediators underlying AD itching is limited.
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Glucocorticoids attenuate itching in chronic skin di-
seases including AD (6–8). The mechanisms underlying 
the pharmacological action of glucocorticoids including 
the inhibition of phospholipase A2 (9) and the regulation 
of the expression of cyclooxygenase (COX)-2, but not 
COX-1 (10), have been elucidated. These findings sug-
gest that arachidonic acid metabolites, which are regula-
ted by glucocorticoids, are involved in the itch sensation.
Thromboxane (TX) A2 is an arachidonic acid metabo-
lite produced by catalysis with COX and TX synthase 
(TXSyn) and is altered spontaneously to form inactive 
TXB2. Additionally, TXA2 exerts its pharmacological 
activity (e.g., platelet aggregation) via the thromboxane 
TXA2 receptor (TP), a G-protein coupled receptor (11) 
also involved in allergic skin inflammation (12). In pa-
tients with pruritic diseases, the serum concentration of 
TXB2, a metabolite (and therefore an indicator) of TXA2, 
is increased (13–16). Moreover, intradermal injection 
of TXA2 elicits scratching, an itch-associated response, 
in mice (17). These results suggest that TXA2 plays an 
important role in the itching sensation that accompanies 
several pruritic skin diseases. However, it remains un-
clear whether TXA2 is involved in AD-associated itching.
NC mice that are maintained for a long time in a 
conventional environment develop chronic dermatitis, 
hyperplasia, dry skin, increased serum IgE levels, mast 
cells in the skin and spontaneous scratching, an itch-
related behavior (18, 19); these features are similar to 
those of AD patients (1–3). In this study, we investigated 
whether TXA2 is involved in spontaneous itching in NC 
mice with AD-like chronic dermatitis.
MATERIALS AND METHODS
Animals
Male NC/Nga mice (14–21 weeks old), purchased from Japan 
SLC (Hamamatsu, Japan), were used in this study. The mice 
were bred in a specific pathogen-free environment at the Di-
vision of Animal Resource and Development, Life Science 
Research Center, University of Toyama, and in a conventional 
environment in the experimental animal room in the Department 
of Applied Pharmacology, University of Toyama. All mice, 
except for the healthy controls, were kept together with mite-
infected mice with chronic dermatitis for 2 weeks at 4–5 weeks 
of age in a conventional environment in the experimental animal 
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room (19). These mice exhibited severe dermatitis after one and 
two months. In one series of experiments, TP receptor-deficient 
mice (TP-R–/–) mice with a C57BL/6 genetic background and 
wild-type mice were used at 11 weeks of age (20). The mice 
were housed in a room with controlled temperature (21–23°C), 
humidity (45–65%), and light cycle (lights on from 08:00 to 
20:00 h). Food and water were freely available. All animal 
experiment procedures were approved by the Committee for 
Animal Experiments at the University of Toyama and Asahi-
kawa Medical University and were conducted in accordance 
with the Guidelines for Proper Conduct of Animal Experiments 
(Science Council of Japan, 2006).
Agents (see Appendix S11)
Primary cultures of mouse keratinocytes (see Appendix S11)
Behavioral experiments (see Appendix S11)
Real-time PCR (see Appendix S11)
Reverse transcription and PCR (see Appendix S11)
Enzyme immunoassay for TXB2
Animals were anesthetized with sodium pentobarbital (80 
mg/kg) and transcardially perfused with phosphate-buffered 
saline (PBS). The skin was isolated using an 8-mm-diameter 
punch, immediately shredded with scissors, and added to 1 ml 
of ice-chilled ethanol containing 10 μM indomethacin and 10 
μM zileuton to inhibit cyclooxygenase and 5-lipoxygenase, 
respectively. Following homogenization, each sample was 
centrifuged at 600 × g at 4°C for 10 min. The supernatant (0.8 
ml) was mixed with 5 ml of distilled water (pH 3.0) and app-
lied to a C18 Sep-Pak cartridge (Waters, Milford, MA, USA) 
equilibrated with methanol. The cartridges were washed with 
hexane followed by distilled water and the lipids were then 
eluted with methyl formate. The eluted fraction was then eva-
porated and the resulting residue was suspended in an enzyme 
immunoassay buffer (Cayman Chemical, Ann Arbor, MI, USA) 
for the assay of TXB2. The amount of TXB2 was determined 
using an enzyme immunoassay kit (Cayman Chemical). In the 
case of cultured keratinocytes, the culture medium was chan-
ged to mouse keratinocyte growth medium (CnT-Prime basal 
medium; CELLnTEC Advanced Cell Systems AG), as the assay 
medium. Samples for the assay of TBX2 were obtained from the 
supernatant 5 min post SLIGRL-NH2 administration. Following 
collection of culture medium, the cultured keratinocytes were 
treated with 1% Triton X-100 to solubilize the cell proteins. 
Total protein concentration was determined using a Bio-Rad 
Protein Assay Kit (Hercules, CA, USA) and TXB2 concentra-
tion was measured using an enzyme immunoassay kit (Cayman 
Chemical). The concentration of TXB2 in keratinocytes was 
normalized to a skin section (8-mm diameter) and total protein 
concentration, respectively.
Immunostaining
Under anesthesia with sodium pentobarbital (80 mg/kg, in-
traperitoneal), the animals were transcardially perfused with 
PBS following by with 4% paraformaldehyde (PFA). The skin 
of the rostral back was isolated, post-fixed with 4% PFA and 
then immersed in 30% sucrose solution for 2 days. The tissue 
was then embedded in Tissue-Tek1 O.C.T. Compound (Sakura 
Fineteck Co., Ltd., Tokyo, Japan) and the frozen samples were 
sectioned at 16 μm with a cryostat (Leica, Wetzlar, Germany). 
The sections were washed with PBS and then treated with 
Protein Block® (DAKO Co., Hamburg, Germany) followed 
by 0.3% Triton X-100 in PBS. The sections were treated with 
anti-TXSyn antibody (Cayman Chemical) at 4°C overnight. 
For some experiments, sections were treated with the antibody 
(Cayman Chemical) pre-incubated with its specific antigen 
prior to staining. Subsequent to washing with PBS, the prepa-
rations were incubated with Alexa Fluor 488-conjugated anti-
rabbit IgG (Life Technologies, Carlsbad, CA, USA) for 1 h at 
room temperature. Fluorescence signals were observed using 
a fluorescence microscope (BX-61/DP70, Olympus, Tokyo, 
Japan). Fluorescent intensity was analyzed with NIH Image 
software (National Institute of Health, Bethesda, MD, USA).
Statistical analysis
Data are presented as mean ± S.E.M. The statistical significance 
of differences between group means was analyzed using the 
Student’s t-test (two groups) or one-way analysis of variance 
(ANOVA) followed by a post-hoc Holm–Šidák test (3 or more 
groups). A p-value < 0.05 was considered statistically significant.
RESULTS
Spontaneous scratching in NC mice with chronic 
dermatitis
Fig. 1A shows the number of spontaneous bouts of 
hind paw scratching towards any region of the body 
in individual healthy and chronic dermatitis NC mice. 
Although the healthy mice did not exhibit spontaneous 
scratching, most age-matched chronic dermatitis mice 
exhibited apparent spontaneous scratching. In the fol-
lowing experiments, we used healthy NC mice that 
were given intradermal injections of SLIGRL-NH2. In 
other experiments, healthy and chronic dermatitis NC 
mice were compared.
Fig. 1. (A) Comparison of spontaneous scratching between healthy and 
dermatitis mice. Spontaneous hind paw scratching towards any region of 
the body was counted for 1 h at 21 weeks of age. Healthy mice were kept 
under specific pathogen-free (SPF) conditions and dermatitis mice were 
transferred to a conventional environment (CNV) at 4–5 weeks of age. 
Open circles represent the values for individual animals; the horizontal bars 
represent the means (n = 10 each). *p < 0.05 (Student’s t-test). (B) Effects of 
ONO-3708 on spontaneous scratching in NC mice with chronic dermatitis. 
Either ONO-3708 or the vehicle (VH) was administered orally 1 h prior to 
observation. The broken line represents the mean number of scratch bouts 
in healthy mice. Values represent the mean and S.E.M. (n = 16). *p < 0.05, 
as compared with VH-treated mice (Holm–Šidák test).1http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-2437
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Effects of TP antagonist on spontaneous scratching in 
NC mice with chronic dermatitis
The TP receptor antagonist ONO-3708 (30 or 100 mg/
kg) significantly inhibited spontaneous scratching in 
NC mice with chronic dermatitis, compared with the 
vehicle-treated group (Fig. 1B).
Effects of the TP receptor antagonist and TP receptor-
deficiency on SLIGRL-NH2-induced scratching
PAR2 is involved in spontaneous scratching in NC 
mice with chronic dermatitis (24). Intradermal injec-
tion of SLIGRL-NH2 (100 nmol/site), a PAR2 agonist 
peptide, elicited scratching in healthy NC mice (Fig. 2). 
ONO-3708 (30 and 100 mg/kg) significantly inhibited 
scratching induced by SLIGRL-NH2 compared with the 
vehicle-treated group (Fig. 2 A). While SLIGRL-NH2 
(100 nmol/site) induced scratching in wild-type mice, 
the scratching was decreased by approximately 75% 
in TP-deficient mice, compared with that in wild-type 
mice (Fig. 2B). The mRNA expressions of TP receptor, 
TXSyn and PAR2 in the skin and DRG in wild-type 
and TP-deficient mice are shown in Fig. S11. 
Expression of TXSyn mRNA and TXB2 concentration in 
NC mouse skin
The expression of TXSyn mRNA (Fig. 3A) and TXB2, 
a stable degradation product of TXA2 (Fig. 3B), were 
significantly higher in the lesional skin of NC mice with 
chronic dermatitis than in the skin of healthy NC mice.
Distribution of TXSyn in the skin of NC mice
In contrast to healthy skin, the lesional skin of NC mice 
with chronic dermatitis exhibited epidermal hyperplasia 
(Fig. 4). Immunohistochemical staining and fluorescent 
Fig. 2. Effects of the thromboxane (TX) A2 receptor (TP) antagonist 
ONO-3708 on SLIGRL-NH2-induced scratching. (A) SLIGRL-NH2 (100 
nmol/site) was injected intradermally into the rostral back of healthy NC 
mice. ONO-3708 or the vehicle (VH) was administered orally 1 h prior to 
SLIGRL-NH2 injection. The broken line represents the mean number of 
scratch bouts in the saline-injected group. Values represent the mean and 
S.E.M. (n = 8). *p < 0.05, as compared with VH-treated group (Holm–Šidák 
test). (B) SLIGRL-NH2 (100 nmol/site) or saline was injected intradermally 
into the rostral back of TP-deficient (TP-R–/–) or the wild-type (WT) mice.
Values represent the mean and S.E.M. (n = 6–8). *p < 0.05, as compared 
with saline-injected group (WT), #p < 0.05, as compared with SLIGRL-
injected group (WT) (Holm–Šidák test).
Fig. 3. (A) Expression level of TXSyn mRNA in the skin of healthy 
(lesional)  or dermatitis mice (NC). The mRNA levels were determined 
in 8-mm diameter punch skin of the rostral back by real-time PCR. The 
mRNA levels were normalized to the level of glyceraldehyde-3-phosphate 
dehydrogenase in each sample and then to the mean level observed in 
the healthy control mice. Values represent the means and S.E.M. (n = 9). 
*p < 0.05 (Student’s t-test). (B) TXB2 concentration in the skin of healthy or 
dermatitis (lesional) mice. The TXB2 concentration in the rostral back skin 
of healthy or dermatitis mice was measured by an enzyme immunoassay. 
Values represent the mean and S.E.M. (n = 10). *p < 0.05 (Student’s t-test).
Fig. 4. Thromboxane synthase (TXSyn). Representative images of TXSyn 
(green) immunostaining in the skin of healthy (Top) and dermatitis (Middle) 
NC mice. Skin samples of dermatitis NC mice were also immunostained 
with the pre-absorbed TXSyn antibody (Bottom). Dotted lines indicate 
the boundary between the dermis (D) and epidermis (ED). The values 
in parenthesis indicate the fluorescence intensity ratio in the ED and D 
(ED/D); scale bar = 100 μm.
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intensity analysis in the epidermis and dermis revealed 
that TXSyn is predominantly expressed in epidermal 
keratinocytes (Fig. 4). Staining was eliminated when 
pre-absorbed antibody was used (Fig. 4 bottom).
The production of TXA2 induced by SLIGRL-NH2 in 
primary cultures of mouse keratinocytes
Both TXSyn and PAR2 mRNA were expressed in 
primary cultures of mouse keratinocytes (Fig. 5A). 
SLIGRL-NH2 (20–200 μM) induced TXA2 production, 
as determined by an increase in TXB2 concentration 
in primary cultures of mouse keratinocytes (Fig. 5B). 
SLIGRL-NH2-induced TXA2 production was signifi-
cantly inhibited by the TXSyn inhibitor sodium ozagrel 
(1–10 μM) (Fig. 5B). In addition, the PAR2-neutralized 
antibody (Fig. S21) also attenuated the TXA2 produc-
tion inhibited by SLIGRL-NH2 (Fig. 5C).
DISCUSSION
Responses to pruritogens differ among mouse species 
(25). An intradermal injection of histamine (10–1,000 
nmol/site) did not induce scratching in healthy NC mice 
(Fig. S31), suggesting that NC mice respond minimally 
to histamine. Thus, pruritogens other than histamine are 
involved in the observed spontaneous scratching in NC 
mice with chronic dermatitis. The results of the present 
study show that the TP receptor antagonist ONO-3708 
inhibits spontaneous scratching in NC mice with 
chronic dermatitis. In healthy NC mice, an intradermal 
injection of the TXA2 analogue U-46619 (1–100 nmol/
site) elicited dose-dependent scratching (Fig. S31). Ad-
ditionally, U-46619-induced scratching was inhibited 
by ONO-3708 (Fig. S41). ONO-3708 inhibits receptor 
binding of U-46619 but not TXB2, leukotriene D4, or 
prostaglandin D2 and E1 (21, 22), suggesting that the 
action of U-46619 is mediated via the TP receptor. Both 
TXSyn mRNA expression and TXA2 production, as 
gauged by TXB2 concentration, were increased in the 
skin of NC mice with chronic dermatitis. These results 
suggest that TXA2 and its receptor are involved in spon-
taneous itching in NC mice with chronic dermatitis.
TXSyn is a key enzyme involved in the synthesis of 
TXA2 from prostaglandin H2, a metabolite of arachido-
nic acid (26). TXSyn was predominately expressed in 
epidermal keratinocytes in the skin of both healthy and 
dermatitis NC mice. Previously, we have also shown 
that keratinocytes express TXSyn in ICR mice, which 
are untreated healthy mice (17). Mast cells in the skin 
also express TXSyn and produce TXA2 via immuno-
logical stimulation (27). However, the TXA2 content is 
much lower than the contents of other arachidonic acids 
metabolites, such as prostaglandin D2 and leukotriene C4 
(27). In addition, no immunoreactivity against TXSyn 
was observed in the dermis, where the mast cells are 
distributed, of either healthy or dermatitis NC mice. 
Therefore, these results do not support the involvement 
of mast cell TXA2 in itching in NC mice with chronic 
dermatitis. However, it is still possible that mast cell-
derived TXA2 is involved in itching associated with 
dermatitis. Taken together, these findings indicate that 
epidermal keratinocytes constitute the main source of 
TXA2 production in lesional skin.
In the skin of NC mice with chronic dermatitis, 
expression of TXSyn mRNA was increased. The AP-1 
Fig. 5. The production of thromboxane (TX) A2 induced by SLIGRL-NH2 in 
primary cultures of mouse keratinocytes. (A) The expression levels of TX 
synthase (TXSyn) and proteinase-activated receptor 2 (PAR2) mRNA were 
determined using reverse transcription (RT)-PCR. Typical examples of the 
bands of RT-PCR products for TXSyn, PAR2 and GAPDH (glyceraldehyde-
3-phosphate dehydrogenase) mRNA are seen in the gel. (B) Effects of the 
TXSyn inhibitor sodium ozagrel on SLIGRL-NH2-induced TXA2 production. 
Sodium ozagrel was applied 5 min prior to the application of SLIGRL-NH2. 
Since TXA2 is altered spontaneously to form inactive TXB2, the TXB2 
content in the assay medium was measured using an enzyme immunoassay. 
Values represent the mean and S.E.M. (n = 6). *p < 0.05, as compared with 
assay medium alone, #p < 0.05, as compared with SLIGRL-NH2 (200 
μM) alone (Holm–Šidák test). (C) Effect of PAR2-neutralized antibody 
on SLIGRL-NH2-induced TXA2 production. All cultures were exposed to 
Non-specific IgG (nIgG) (1:500) or PAR2-neutralized antibody (PAR2ab, 
1:500) 10 min prior to the application of SLIGRL-NH2 (200 μM). Values 
represent the means and S.E.M. (n = 6). *p < 0.05, as compared with nIgG 
alone, #p < 0.05, as compared with nIgG+SLIGRL-NH2 (Holm–Šidák test).
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family of transcription factors plays an important role 
in the promotor activity for TXSyn (28). Increased 
immunoreactivity to AP-1-related transcription factors 
(e.g., Jun D, c-Fos, Fos B, Fra-1, and Fra-2) has been 
observed in the epidermis (29) of AD patients com-
pared to that of healthy subjects. Jun D and c-Fos, in 
particular, exhibit strong cytoplasmic positivity in the 
epidermis of AD patients (29). Thus, the increase in 
AP-1 expression may be related to the elevated TXSyn 
expression in atopic dermatitis-like skin lesions. 
The mechanisms underlying TXA2 production in le-
sional skin are not completely understood. Previously, 
we have demonstrated that serine proteinase and PAR2 
are involved in itch-related responses in NC mice with 
chronic dermatitis (24). In this study, the PAR2 agonist 
peptide SLIGRL-NH2-induced itch-related responses 
were inhibited by a TP receptor antagonist in healthy 
NC mice and were decreased in TP receptor-deficient 
mice, suggesting that TXA2 is involved in PAR2-related 
responses. PAR2 is predominately expressed in epider-
mal keratinocytes (24). In primary cultures of NC mouse 
keratinocytes, the application of a PAR2 agonist peptide 
induced the production of TXA2, and this response was 
inhibited by the TX inhibitor and the PAR2-neutralizing 
antibody. Thus, PAR2 activation may be involved in 
the production of TXA2 in keratinocytes. PAR2 is ac-
tivated by trypsin-like serine proteases (e.g., tryptase 
and kallikrein 5) and a synthetic PAR2-tethered ligand 
known as PAR2 agonist peptide (30–32). In NC mice 
with chronic dermatitis, tryptase from mast cells (24) 
and kallikrein 5 from keratinocytes (33) are involved in 
itching behavior, suggesting that these serine-proteases 
play an important role in the production of TXA2. There 
are at least two possible pathways by which keratinocy-
tes produce TXA2 following PAR2 stimulation. PAR2 
is a G-protein-coupled receptor (30) and its activation 
increases the level of free intracellular Ca2+ ions (30, 
34, 35). Thus, the activation of phospholipase A2 via 
increased free intracellular Ca2+ ions (36) may promote 
TXA2 production. Production may also occur via Rho 
kinase-mediated phospholipase A2 activation (37); the 
activation of PAR2 stimulates Rho kinase activity (38). 
In addition to the increase in TXSyn expression, these 
two pathways may contribute to the production of TXA2 
in the lesional skin of NC mice with chronic dermatitis.
In the skin, TP receptors are predominantly expressed 
in keratinocytes and primary afferent neurons (17) (Fig. 
S31). In addition, TP receptors are expressed in small-
size neurons in the dorsal root ganglion (17); these have 
chiefly unmyelinated C-fibers (39, 40), which play an 
important role in itch signaling (41, 42). The application 
of the TXA2 analogue U-46619 increases the concentra-
tion of free intracellular Ca2+ ions, which is inhibited by 
the TP receptor antagonist, in primary cultures of dorsal 
root ganglion neurons (17). The action of U-46619 is also 
inhibited by L-type calcium channel blockers, sugges-
ting that the activation of TP receptors elicits membrane 
depolarization (43). These observations suggest that 
TXA2 acts on primary afferent neurons or through both 
autocrine and paracrine mechanisms in keratinocytes. 
Additionally, intra-epidermal neurites increase in the skin 
of NC mice with chronic dermatitis (44) and patients with 
atopic dermatitis (45, 46). These findings also support 
the hypothesis that TXA2 released from keratinocytes 
acts directly on primary afferent neurons.
In conclusion, we demonstrated that TXA2 produced 
by epidermal keratinocytes is involved in spontaneous 
itch-related behavior in NC mice with AD-like skin 
lesions. Moreover, we found that the serine protease-
PAR2 system partially contributes to the production of 
TXA2. PAR2, TXSyn and TP receptor may constitute 
potential new targets for the development of antipruritic 
drugs for AD.
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